School of Breast Oncology® Online Curriculum

Release Date: January 29, 2021
Expiration Date: January 29, 2022

To register for the 2021 conference, please click here.

Repurposing Statement

If you previously attended and received credit for the live CME-/CE-certified conference, 18th Annual School of Breast Oncology^®, which was held from November 5 to November 7, 2020, please note that you will not receive credit for completing this activity. Participants who take part in an identical activity, even in order to validate learning or to clarify specific topics, cannot claim, nor will Physicians’ Education Resource^®, LLC (PER^®), award, duplicate credit for the activity

Activity Overview

An increasing number of oncologists are focusing their clinical practices on the treatment of breast cancer, creating a need for specialized education. The School of Breast Oncology^®, which has been held annually since 2003, was developed to advance patient care by providing a curriculum-based program focused exclusively on breast cancer clinical management. This intensive 3-day interactive program will provide a comprehensive review of data on the most important aspects of breast cancer biology, diagnostics, prevention and treatment, with lectures emphasizing clinical implications presented by leading clinical investigators.

Acknowledgement of Commercial Support

This educational activity is supported by educational grants from AstraZeneca; Daiichi Sankyo Inc.; Eisai Inc.; Lilly; MacroGenics, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation.; Pfizer Inc; Puma Biotechnology, Inc., and Seagen Inc. (formally Seattle Genetics, Inc.)

For further information concerning Lilly grant funding, visit lillygrantoffice.com.

Target Audience

This educational program is directed toward medical, radiation, and surgical oncologists whose primary practice focus is breast cancer and who intend to reinforce their knowledge base and expand their expertise in breast cancer diagnosis, treatment, and management. Participants will be primarily oncologists or fellows in training whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the pathogenesis and management of breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Review breast cancer biology, staging, and prognostic and/or predictive markers, in order to better individualize therapy and counsel patients regarding conventional and investigational treatment options
• Integrate biomarkers, molecular assays, and other risk assessment tools into treatment decision-making algorithms to optimize outcomes for patients with breast cancer
• Discuss current and evolving imaging options for diagnosing, staging, and monitoring breast cancer
• Incorporate current guidelines and evolving evidence on local treatment options, including new approaches in surgery and radiation therapy, into the management of patients with breast cancer
• Individualize selection of systemic therapies for patients with early-stage or advanced/metastatic breast cancer by taking into consideration efficacy and safety, as well as patient characteristics and tumor subtype
• Evaluate emerging clinical data and evolving strategies for the treatment of breast cancer, and apply clinical trial data appropriately in order to optimize the outcome of individual patients
• Utilize supportive care strategies for preventing and managing treatment-related toxicities in patients receiving treatment for breast cancer
• Facilitate awareness of clinical trial opportunities based on knowledge of emerging agents and variances in care in the field of breast cancer management

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Program Chair

Joyce O'Shaughnessy, MD
Celebrating Woman Chair in Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
Co-Chair, Breast Cancer Research Program
The US Oncology Network
Dallas, TX

Disclosures: Consultant: Novartis Pharmaceuticals, AstraZeneca, Celgene, Eli Lilly & Company, Merck & Co., Pfizer, Seattle Genetics.

Faculty

Carey K. Anders, MD
Division of Medical Oncology
Medical Director, Duke Center for Brain and Spine Metastasis
Translating Duke Health Scholar
Duke Cancer Institute
Durham, NC

Disclosures: Grant Research Support: Puma Biotechnology, Eli Lilly & Company, Merck & Co., Seattle Genetics, Nektar Therapeutics, Tesaro, G1 Therapeutics, Zion, Novartis Pharmaceuticals, Pfizer; Consultant: Puma Biotechnology, Genentech, Esai, Ipsen, Seattle Genetics, AstraZeneca, Novartis Pharmaceuticals; Other: Royalties: UpToDate, Jones & Bartlett Learning.

Douglas W. Arthur, MD, FABS, FASTRO
Professor and Chairman
Florence and Hyman Meyers Chair
Department of Radiation Oncology
Massey Cancer Center
Virginia Commonwealth University
Richmond, VA

Disclosures: Other: Advanced Radiation Therapy - scientific advisor.

Timothy D'Alfonso, MD
Associate Attending Pathologist
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: PAIGE.AI.

David M. Euhus, MD, FACS
Professor of Surgery
Chief, Breast Surgery
Division of Surgical Oncology
Johns Hopkins Medicine
Baltimore, MD

Disclosures: no relevant financial relationships with commercial interest.

Carol Fabian, MD
Distinguished Professor of Hematology/Oncology
Director, Breast Cancer Prevention and Survivorship Centers
Morris Family Endowed Chair, Cancer Prevention
University of Kansas Medical Center
Kansas City, KS

Disclosures: Grant Research Support: National Cancer Institute, Breast Cancer Research Foundation.

William J. Gradishar, MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology and Professor of Medicine
Chief, Division of Hematology and Oncology
Deputy Director, Clinical Network
Director, Maggie Daley Center for Women's Cancer Care
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL

Disclosures: Advisory board/ DSMB: Roche/Genentech, AstraZeneca, Seattle Genetics, Immunomedics, Novartis; Other: BCRF funding.

Karin Hahn, MD, MSc, MPH, FRCPC
Chief, Division of Medical Oncology
London Health Sciences Center
Associate Professor, Department of Oncology
Schulich School of Medicine and Dentistry
Western University
Ontario, Canada

Disclosures: no relevant financial relationships with commercial interests.

Eleanor Harris, MD
Professor, Department of Radiation Oncology
Case Western Reserve University
Vice Chair, Clinical Programs and Quality
Department of Radiation Oncology
Director, Breast Cancer Radiation Oncology
UH Cleveland Medical Center
Cleveland, OH

Disclosures: no relevant financial relationships with commercial interests.

Claudine Isaacs, MD
Associate Professor of Medicine and Oncology
Co-Director, Breast Cancer Program
Medical Director, Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Disclosures: Grant Research Support: Tesaro, Pfizer; Consultant: Pfizer, AstraZeneca, Genentech, Novartis, Seattle Genetics, PUMA, Sanofi, Eisai; Speakers Bureau: Genentech.

Henry M. Kuerer, MD, PhD, FACS
Professor of Surgery
PH and Fay Etta Robinson Distinguished Professor Cancer Research
Executive Director, Department of Breast Programs
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: National Cancer Institute; Other: Annals of Surgical Oncology (Editorial Board); American Society of Breast Surgeons (Chair, Publications Committee); McGraw- Hill Publishing.

Charles Loprinzi, MD
Regis Professor of Breast Cancer Research
Medical Oncologist
Mayo Clinic
Rochester, MN

Disclosures: Grant Research Support: Bristol-Myers Squibb, Pfizer; Consultant: PledPharma, Metys, Asahi Kasei Pharma, OnQuality Pharma.

Terry P. Mamounas, MD, MPH, FACS
Professor of Surgery
University of Central Florida College of Medicine
Clinical Professor of Clinical Sciences
Florida State University College of Medicine
Medical Director, Comprehensive Breast Program
Orlando Health UF Health Cancer Center
Orlando, FL

Disclosures: Consultant: Exact Sciences, Genentech/Roche, Biotheranostics, Merck & Co., Daiichi Sankyo, Puma Biotechnology; Speakers Bureau: Exact Sciences.

Anne McTiernan, MD, PhD
Full Professor (Research), Epidemiology and Geriatrics
University of Washington Schools of Public Health and Medicine
Member, Epidemiology
Fred Hutchinson Cancer Research Center
Seattle, WA

Disclosures: Shareholder: Merck (husband).

Hyman Muss, MD
Professor of Medicine
Mary Jones Hudson Distinguished Professor of Geriatric Oncology
Director, Geriatric Oncology
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill
Chapel Hill, NC

Disclosures: no relevant financial relationships with commercial interests.

Ruth O’Regan, MD
Professor of Medicine
Chief, Hematology and Medical Oncology
Carbone Comprehensive Cancer Center
University of Wisconsin
Madison, WI

Disclosures: Grant/Research Support: Eisai, Pfizer, Novartis Pharmaceuticals, Seattle Genetics; Consultant: Pfizer, Genomic Health, Biotheranostics, Novartis Pharmaceuticals, Eli Lilly & Company, Puma Biotechnology, Genentech, Immunomedics, MacroGenics.

Michael F. Press, MD, PhD
Professor, Department of Pathology
Co-Leader, Women’s Cancers Program
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Disclosures: Grant Research Support: Cepheid; Consultant: Science Branding Communications, Biocartis, Zymeworks, Cepheid; Eli Lilly & Company, Puma Biotechnology, Merck & Co, AstraZeneca, Novartis Pharmaceuticals; Shareholder: Torl Biotherapeutics.

Elizabeth Rafferty, MD
Director of Breast Imaging Programs
L&M Radiology
Medical Director, Women's Health Imaging
Andover Medical Center
Andover, MA

Disclosures: Grant Research Support: Hologic Inc, for investigation of tomosynthesis; Consultant: Hologic Inc.

Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant Research Support: Pfizer, Merck & Co., Novartis Pharmaceuticals, Eli Lilly & Company, Genentech, OBI Pharma, Odonate Therapeutics, Daiichi Sankyo, Eisai, Seattle Genetics, MacroGenics, Sermonix Pharmaceuticals, and Immunomedics; Consultant: Samsung and Puma Biotechnology (Limited consulting); Other: Travel: Daiichi Sankyo, Mylan, Pfizer, Merck & Co., AstraZeneca, Novartis Pharmaceuticals, MacroGenics.

Hani Sbitany, MD
Associate Professor of Surgery
Plastic and Reconstructive Surgery
Mount Sinai
New York, NY

Disclosures: Consultant: Allergan, Inc.

David M. Schuster, MD
Professor
Director, Division of Nuclear Medicine and Molecular Imaging
Department of Radiology and Imaging Sciences
Emory University
Atlanta, GA

Disclosures: Grant Research Support: Participates through the Emory Office of Sponsored Projects in sponsored grants, including those funded or partially funded by Blue Earth Diagnostics, Nihon Medi-Physics Co., Telix Pharmaceuticals, Advanced Accelerator Applications, FUJIFILM Pharmaceuticals U.S.A., Amgen; Consultant: Syncona, AIM Specialty Health Global Medical Solutions Taiwan, Progenics Pharmaceuticals.

Joseph A. Sparano, MD
Professor of Medicine and Obstetrics, Gynecology, and Women's Health
Albert Einstein College of Medicine
Associate Chairman, Clinical Research
Department of Oncology
Montefiore Medical Center
Bronx, NY

Disclosures: Grant Research Support: Deciphera, Prescient Therapeutics; Consultant: Astra Zeneca, Novartis, Pfizer, Genentech/Roche, Eli Lilly, Celgene, CStone, Cardinal Health, Epic Sciences.

Sara M. Tolaney, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Associate Director, Susan F. Smith Center for Women's Cancers
Director, Clinical Trials, Breast Oncology
Director, Breast Immunotherapy Clinical Research
Senior Physician
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Grant Research Support: Genentech, Eli Lilly & Company, Novartis Pharmaceuticals, AstraZeneca, Merck & Co., Pfizer, Nektar Therapeutics, Exelixis, Bristol Myers Squibb, Eisai, Cyclacel Pharmaceuticals, Immunomedics, Odonate Therapeutics, Seattle Genetics; Consultant: Puma Biotechnology, Nektar Therapeutics, Merck & Co., AstraZeneca, Daiichi Sankyo, NanoString Technologies, Eli Lilly & Company, Pfizer, Novartis Pharmaceuticals, Eisai, Genentech, Immunomedics, Sanofi, Celldex Therapeutics, Paxman, Seattle Genetics, Odonate Therapeutics, Bristol Myers Squibb, G1 Therapeutics, Silverback Therapeutics, AbbVie, Athenex, OncoPep, Samsung Bioepsis, Kyowa Kirin Co., CytomX Therapeutics.

Tiffany A. Traina, MD
Associate Professor of Medicine
Weill Cornell Medicine
Associate Attending Physician
Vice Chair, Oncology
Department of Medicine
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant Research Support: Eisai, Pfizer, Novartis, Innocrin Pharma, AstraZeneca, Astellas Pharma, Immunomedics, Genentech/Roche, Daiichi Sankyo, Carick Pharmacy; Consultant: Genentech, Pfizer, AstraZeneca, Merck, Puma Biotechnology, Advaxis, Celgene, Innocrin Pharma, Genomic Health, Bristol-Myers Squibb, Samsung, Athenex, Aduro Biotech, Halozyme, Daiichi Sankyo, Ionis, Seattle genetics; Speakers Bureau: Roche/Genentech.

Catherine Van Poznak, MD
Associate Professor
Division of Hematology and Oncology
Medical Oncologist
U-M Rogel Cancer Center
University of Michigan
Ann Arbor, MI

Disclosures: Grant Research Support: Bayer; Other: Novartis (uncompensated) phase IV study steering committee.

Jeffrey N. Weitzel, MD
Professor of Oncology and Population Sciences
Dr. Norman & Melinda Payson Professorship in Medical Oncology
Director, Division of Clinical Cancer Genomics
City of Hope Cancer Center
Duarte, CA

Disclosures: Grant Research Support: no relevant financial relationships with commercial interests.

Julia S. Wong, MD, FASTRO
Assistant Professor
Dana-Farber Cancer Institute/Brigham & Women’s Hospital
Harvard Medical School
Boston, MA

Disclosures: Other: Writer for UpToDate (Wolters Kluwer).

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.